New Delhi, on Monday, Drug firm Hetero launched a biosimilar of 'Bevacizumab', used in treating metastatic colorectal cancer (mCRC), under the brand name 'CizumabTM'. Drug Controller General of India (DCGI) approved the product and is recommended as a first-line treatment for mCRC.

Hetero Group of Companies CMD BPS Reddy said, "It has been an exciting journey for us in biologics. Hetero's Bevacizumab is the third product in our biologics portfolio, after Darbepoetin alfa and Rituximab. We believe CizumabTM will be a cost-effective treatment option to patients".

According to company, with two strengths, 100 mg and 400 mg in a single dose, the product will be made available to patients.

Hetero Healthcare Limited, a group company of Hetero will distribute the product.

Hyderabad-based Hetero is one of the world's largest producer of anti-retroviral drugs for the treatment of HIV/AIDS.